The introduction of HER2-targeted therapy for breast and gastric patients with ERBB2
(HER2) amplification/overexpression has led to dramatic improvements in oncologic …

With the increasing availability of genomics, routine analysis of advanced cancers is now
feasible. Treatment selection is frequently guided by the molecular characteristics of a …

Background Patients with advanced rare cancers have poor prognosis and few treatment
options. As immunotherapy is effective across multiple cancer types, we aimed to assess …

Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We
reviewed the medical records of patients with solid tumors displaying CCNE1 amplification …

PURPOSE Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic
target in breast and gastric and gastroesophageal junction cancers. However, less is known …

Background: Wee1 kinase, which prevents premature mitotic entry by inhibiting cyclin-
dependent kinases (CDKs), may be essential when cyclin E1 is overexpressed in order to …

Somatic mutation profiling of tumors is performed in both clinical and research settings, often
to identify patients with cancer who are candidates for targeted therapies. Profiling …

Abstract Background: Sapanisertib (CB-228/TAK-228) is a potent, selective ATP-competitive,
dual inhibitor of mTORC1/2. Metformin is thought to inhibit the mTOR pathway through …

Introduction Genomic profiling is performed in patients with advanced or metastatic cancer,
in order to direct cancer treatment, often sequencing tumor-only, without a matched germline …

Background: Immune checkpoint inhibitors (ICI) such as anti-PD-1/PD-L1 antibodies have
rapidly become a pivotal approach to cancer therapy. Nivolumab is an anti-PD1 antibody …